FINWIRES · TerminalLIVE
FINWIRES

$EW

18 stories mentioning EWUpdated 1d ago

Every FINWIRES story that references EW, newest first.

Insider Trading

Edwards Lifesciences Insider Sold Shares Worth $818,958, According to a Recent SEC Filing

Wayne Markowitz, Corporate Vice President of Japan, Greater China, and Asia Pacific, on July 28, 2026, sold 9,628 shares in Edwards Lifesciences (EW) for $818,958. Following the Form 4 filing with the SEC, Markowitz has control over a total of 21,680 common shares of the company, with 21,680 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1099800/000122520826006777/xslF345X05/doc4.xml

$EW
Research

UBS Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $110 From $90

Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $102.02, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $85.23, Change: $+2.19, Percent Change: +2.64%

$EW
Wire

Edwards Lifesciences Seen Building on Catalyst Pipeline, RBC Says

Edwards Lifesciences (EW) is competitively differentiated and positioned to sustain double-digit growth as product catalysts build through 2027, RBC Capital Markets said in a Thursday note.Meanwhile, Q2 results reinforced that view as transcatheter aortic valve replacement, or TAVR, sales exceeded expectations, supported by market growth and modest share gains, the note said.RBC also pointed to continued clinical momentum and adoption of the Sapien 3 Ultra platform.Regulatory and pipeline developments continue to support its growth outlook, including a final US national coverage determination for TAVR expected in September, trial result and anticipated US approval of Pascal, the note said.RBC raised its 2026 revenue estimate to $6.76 billion and said it continues to expect adjusted EPS of $3.02.RBC reiterated its outperform rating on Edwards Lifesciences and $110 price target.Price: $85.47, Change: $+1.65, Percent Change: +1.97%

$EW
Research

Leerink Partners Upgrades Edwards Lifesciences to Outperform From Market Perform, Adjusts PT to $101 From $87

Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $100.98, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$EW
Wire

Edwards Lifesciences Q2 Adjusted Earnings, Revenue Rise; Q3 Guidance Set

Edwards Lifesciences (EW) reported Q2 adjusted earnings late Thursday of $0.78 per diluted share, up from $0.67 a year earlier.Analysts polled by FactSet expected $0.74.Revenue for the three months ended June 30 was $1.74 billion, up from $1.53 billion a year earlier.Analysts expected $1.70 billion.For Q3, the company expects adjusted EPS of $0.71 to $0.77 on revenue of $1.63 billion to $1.71 billion. Analysts expect EPS of $0.75 on revenue of $1.69 billion.The company reaffirmed full-year 2026 adjusted EPS guidance of $2.95 to $3.05 and now expects revenue of $6.6 billion to $6.9 billion. Analysts expect EPS of $3.01 on revenue of $6.75 billion.

$EW
Wire

Mizuho Adjusts Price Target on Edwards Lifesciences to $105 From $100, Maintains Outperform Rating

Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $99.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $88.46, Change: $-1.64, Percent Change: -1.81%

$EW
Wire

Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says

Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership and the under-penetrated global transcatheter aortic valve replacement market, RBC Capital Markets said in a note Monday.The company's New York Valves presentations reinforced its leadership in clinical evidence and included baseline data from its Progress trial, providing the first detailed look into the moderate aortic stenosis population ahead of the full readout later this year, according to the note.The brokerage estimates there are about 950,000 severe symptomatic aortic stenosis patients in the US, including about 350,000 low-risk patients who could be diagnosed with severe asymptomatic AS, and about 1 million moderate AS patients, suggesting a multi-year runway for growth.Moreover, Edwards' Pascal platform, along with Abbott's (ABT) MitraClip, is positioned to drive expansion in the mitral regurgitation market, which remains notably under-penetrated with room for multiple market participants, the brokerage said.RBC Capital Markets kept an outperform rating on Edwards Lifesciences, with a price target of $100.Price: $91.53, Change: $+0.75, Percent Change: +0.82%

$EW
Wire

Edwards Lifesciences Seen Benefiting From CMS Transcatheter Aortic Valve Replacement Rule, RBC Says

Edwards Lifesciences (EW) is expected to benefit from the Centers for Medicare & Medicaid Services' Proposed Decision Memo for a National Coverage Determination on transcatheter aortic valve replacement, or TAVR, RBC Capital Markets said.The proposal is expected to drive near-term TAVR growth by confirming single-operator procedures and removing coverage with evidence development for symptomatic patients, the brokerage said in a Monday note.The changes are set to improve scheduling, support new site formation, and reduce administrative burden, according to the research note.RBC said its checks indicate the proposal is likely to be adopted and estimated about a 5% increase in TAVR procedures over time from the coverage determination. Further guidelines from the American College of Cardiology and the American Heart Association could also serve as catalysts for the procedure, the firm noted.RBC reiterated its outperform rating and $100 price target on Edwards Lifesciences.Shares of the company were up 3.4% in Tuesday trading.Price: $89.27, Change: $+2.99, Percent Change: +3.47%

$EW
Wire

Edwards Lifesciences Set to Benefit from TAVR Coverage Update, RBC Says

Edwards Lifesciences (EW) is set to benefit from a national coverage determination update in the use of transcatheter aortic valve replacement for aortic stenosis in asymptomatic patients, RBC Capital Markets said in a Thursday note."The TAVR NCD proposed decision memo due by 6/15 is a notable upcoming catalyst that we expect to be positive for EW and the broader TAVR space," the report said.RBC's physician checks suggest coverage changes could drive about 5% growth in national procedure volumes, with the single-operator shift being the most impactful component for procedure efficiency along with site expansion, the note said."Combined with the ACC/AHA guideline update (expected by AHA meeting in Nov'26), we see a favorable setup for TAVR growth acceleration into 2027," the report said. AHA refers to the American Heart Association, and ACC to American College of Cardiology.RBC kept its outperform rating and a $100 price target.Price: $85.89, Change: $-0.09, Percent Change: -0.10%

$EW
Insider Trading

Edwards Lifesciences Insider Sold Shares Worth $2,000,193, According to a Recent SEC Filing

Donald E Bobo Jr, Corporate Vice President, Strategy & Corporate Development, on May 27, 2026, sold 23,145 shares in Edwards Lifesciences (EW) for $2,000,193. Following the Form 4 filing with the SEC, Bobo has control over a total of 152,379 common shares of the company, with 22,798 shares held directly and 129,581 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1099800/000122520826005610/xslF345X05/doc4.xml

$EW
Insider Trading

Edwards Lifesciences Insider Sold Shares Worth $1,472,678, According to a Recent SEC Filing

Donald E Bobo Jr, Corporate Vice President, Strategy & Corporate Development, on May 15, 2026, sold 17,968 shares in Edwards Lifesciences (EW) for $1,472,678. Following the Form 4 filing with the SEC, Bobo has control over a total of 175,524 common shares of the company, with 22,798 shares held directly and 152,726 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1099800/000122520826005463/xslF345X05/doc4.xml

$EW
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Edwards Lifesciences

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month price target at $96, 32x our 2026 EPS forecast, a small premium to EW's three-year historical forward average of 30.2x. Our target represents a multiple to health care equipment peers, supported by attractive EPS growth potential from EW's position in the structural heart disease market, as well as EW's negative net debt position, in our view. We raise our 2026 EPS estimate by $0.04 to $3.00 and raise our 2027 estimate by $0.05 to $3.36. We expect near 11.0% sales growth in 2026, building off of 11.6% growth in 2025, supported by procedure volume growth in the U.S. and abroad. EW anticipates a Q4 U.S. launch of PASCAL (transcatheter valve repair) for tricuspid patients (part of the TMTT segment). The company also sees the TRIFORMIS surgical tricuspid valve launching in 2H 2026 (part of the Surgical segment).

$EW
Wire

Mizuho Securities Adjusts Edwards Lifesciences Price Target to $100 From $95, Maintains Outperform Rating

Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $97.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $83.02, Change: $+3.30, Percent Change: +4.14%

$EW
Wire

Truist Securities Adjusts Price Target on Edwards Lifesciences to $90 From $89, Maintains Hold Rating

Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $97.16, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $84.41, Change: $+4.63, Percent Change: +5.80%

$EW
Research

Research Alert: Edwards Lifesciences: Tavr Sales Expansion Drives Q1 Eps Beat

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Edwards Lifesciences reported strong Q1 results with sales growing 16.7% Y/Y to $1.65B and adjusted EPS of $0.78, beating consensus estimates by $0.05. Operating margin expanded to 31.4% from 29.1% in the prior-year quarter, supported by $500M in quarterly share repurchases. The company benefits from momentum generated by EARLY TAVR study data driving earlier disease intervention, while Boston Scientific's European market exit strengthened EW's TAVR positioning, in our view. EW raised full-year 2026 guidance to 10% constant currency sales growth and $3.00 adjusted EPS midpoint, representing 17% growth vs. 2025. TAVR sales of $1.20B grew 14.4% Y/Y supported by SAPIEN growth globally, with raised guidance to 8% midpoint from 7% previously. TMTT sales surged 51.9% Y/Y driven by PASCAL adoption and higher EVOQUE utilization as procedure volumes rose in the double digits. We expect continued operating margin expansion toward the high end of EW's 28%-29% guidance range in 2026.

$EW
Wire

BTIG Research Adjusts Edwards Lifesciences Price Target to $98 From $103, Maintains Buy Rating

Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $97.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $77.30, Change: $-0.57, Percent Change: -0.73%

$EW
Wire

Mizuho Adjusts Price Target on Edwards Lifesciences to $95 From $100, Maintains Outperform Rating

Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $97.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $77.90, Change: $+0.03, Percent Change: +0.04%

$EW
Insider Trading

Edwards Lifesciences Insider Sold Shares Worth $1,040,544, According to a Recent SEC Filing

Scott B. Ullem, Corporate Vice President, Chief Financial Officer, on April 09, 2026, sold 13,000 shares in Edwards Lifesciences (EW) for $1,040,544. Following the Form 4 filing with the SEC, Ullem has control over a total of 306,017 common shares of the company, with 39,699 shares held directly and 266,318 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1099800/000122520826004476/xslF345X05/doc4.xml

$EW

Track with the FINWIRES app suite

FolioX
FolioX
Track EW in your portfolio
WheelAI
WheelAI
Analyze EW options with the wheel strategy
StockInsider
StockInsider
See market sentiment on EW